| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -7.4 | -4.8 |
| Net income | -7.4 | -4.8 |
| EPS (diluted, $ a share) | $-0.17 | $-0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ESLA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Estrella Immunopharma, Inc.: key numbers
- Share price
- $0.3800Close, Nov 16
- Market cap
- $16.7M
- Shares outstanding
- 43.97MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Estrella Immunopharma, Inc.
All →Estrella Immunopharma Leadership Change
Estrella Immunopharma appointed Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board, effective October 25, 2026. She succeeds Cheng Liu, Ph.D., who transitioned to the role of Chief Scientific Officer while remaining President and a director. Ms. Pussinen's employment agreement includes an initial base salary of $250,000 with automatic increases tied to future funding milestones.